[1] McLean MH, El-Omar EM. Genetics of gastric cancer [J]. Nat Rev Gastroenterol Hepatol, 2014, 11(11):664-674.
[2] Kalnina Z, Meistere Ⅰ, Kikuste Ⅰ, et al. Emerging blood-based biomarkers for detection of gastric cancer [J]. World J Gastroenterol, 2015, 21(41):11636-11653.
[3] Hichino A, Okamoto M, Taga S, et al. Down-regulation of claudin-2 expression and proliferation by epigenetic inhibitors in human lung adenocarcinoma A549 Cells [J]. J Biol Chem, 2017, 292(6):2411-2421.
[4] He P, Li K, Li SB, et al. Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer [J]. Int J Oncol, 2018, 52(4):1305-1316.
[5] Yao J, Qian CJ, Ye B, et al. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism [J]. Life Sci, 2012, 91(56):186-193.
[6] Noh H, Park J, Shim M, et al. Trichostatin A enhances estrogen receptor-alpha repression in MCF-7 breast cancer cells under hypoxia [J]. Biochem Biophys Res Commun, 2016, 470(3):748-752.
[7] Kahr Ⅰ, Vandepoele K, van Roy F. Delta-protocadherins in health and disease [J]. Prog Mol Biol Transl Sci, 2013, 116(2013):169-192.
[8] Chen Y, Xiang H, Zhang Y, et al. Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer [J]. Clin Exp Metastasis, 2015, 32(5):417-428.
[9] Wang C, Tao B, Li S, et al. Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion [J]. J Mol Neurosci, 2014, 52(2):250-260.
[10]Zhu P, Lv J, Yang Z, et al. Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma [J]. Biochem Biophys Res Commun, 2014, 452(3):567-574.
[11]Lü J, Zhu P, Zhang X, et al. PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma [J]. Mol Med Rep, 2017, 16(4):4475-4482.
[12]Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi [J]. Front Oncol, 2018, 8:92.
[13]Codd R, Braich N, Liu J, et al. Zn(Ⅱ)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A [J]. Int J Biochem Cell Biol, 2009, 41(4):736-739.
[14]Zhang J, Liu Y, Zhang J, et al. FOXQ1 promotes gastric cancer metastasis through upregulation of Snail [J]. Oncol Rep, 2016, 35(6):3607-3613.
[15]Zheng JX, Zhu Q, Liu Ch, et al. Expression of interleukin -34/colony stimulating factor -1R in the process of transforming growth factor -β1 inducing A549 cells transition [J]. Acta Anatomica Sinica, 2014, 45(3): 393-397. (in Chinese)
郑金旭, 朱勤, 刘超, 等. 白细胞介素-34/集落刺激因子-1R在转化生长因子-β1诱导A549细胞上皮-间质转化中的表达 [J]. 解剖学报, 2014, 45(3): 393-397.
[16]Okubo K, Uenosono Y, Arigami T, et al. Clinical significance of altering epithelial-mesenchymal transition in metastatic lymph nodes of gastric cancer [J]. Gastric Cancer, 2017, 20(5):802-810.
[17]Zhu YW, Yan JK, Li JJ, et al. Knockdown of radixin suppresses gastric cancer metastasis in vitro by up-regulation of E-cadherin via NF-κB/Snail pathway [J]. Cell Physiol Biochem, 2016, 39(6):2509-2521.
[18]Pirooz HJ, Jafari N, Rastegari M, et al. Functional SNP in microRNA-491-5p binding site of MMP9 3'-UTR affects cancer susceptibility [J]. J Cell Biochem, 2018, 119(7):5126-5134.
[19]Huang Q, Lan F, Wang X, et al. IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9 [J]. Mol Cancer, 2014, 13:18.
|